tradingkey.logo

Cytek Biosciences Inc

CTKB
View Detailed Chart

4.090USD

+0.170+4.34%
Close 09/18, 16:00ETQuotes delayed by 15 min
520.19MMarket Cap
LossP/E TTM

Cytek Biosciences Inc

4.090

+0.170+4.34%
Intraday
1m
30m
1h
D
W
M
D

Today

+4.34%

5 Days

-0.97%

1 Month

+0.74%

6 Months

-3.54%

Year to Date

-36.98%

1 Year

-19.17%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated: 2025-09-18

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
91 / 207
Overall Ranking
231 / 4721
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 5 analysts
Buy
Current Rating
5.125
Target Price
+30.74%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 22.20% year-on-year.
Fairly Valued
The company’s latest PE is -77.76, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 88.51M shares, decreasing 10.46% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 7.74M shares of this stock.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content and high-sensitivity cell analysis utilizing its Full Spectrum Profiling (FSP) technology. Its FSP platform includes its core instruments, the Cytek Aurora and Northern Lights systems; its cell sorter, the Cytek Aurora CS; the Cytek Orion reagent cocktail preparation system; the flow cytometer and imaging products under the Amnis and Guava brands; and reagents, software and services to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Cytek Northern Lights systems are flow cytometers that deliver high-resolution, high-content, and high-sensitivity cell analysis. Its Cytek Aurora CS is a cell sorter that leverages the detection and sensitivity capabilities of its FSP technology to isolate living cell populations from lower to higher complexity panels beyond 40 biomarkers.
Ticker SymbolCTKB
CompanyCytek Biosciences Inc
CEODr. Wenbin Jiang, Ph.D.
Websitehttps://cytekbio.com
KeyAI